跳至主要内容
临床试验/NL-OMON46262
NL-OMON46262招募中不适用

Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomised double-blind placebo-controlled trial. - Hit hard & Early

Radboud Universitair Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age >= 18 years
  • - Fulfilling VEDOSS criteria:
  • Raynauds* Phenomenon AND
  • Positive for disease specific auto antibodies (anti-centromere or anti-topoisomerase antibodies) AND
  • Systemic- sclerosis specific nail fold capillaroscopic findings
  • - Puffy fingers < 3 years duration
  • - modified Rodnan Skin Score =0

排除标准

  • - Presence of acrosclerosis, acrosteolysis and digital ulcers
  • - Presence of anti-RNA polymerase III auto antibodies
  • - Previous systemic treatment for SSc, namely methotrexate, prednisone (> 14 days in previous 6 months), mofetyl mycophenolate and cyclophosphamide.
  • - Clinically significant internal organ involvement: DLCO< 80% predicted, VC < 70% predicted, renal dysfunction with GFR < 60 ml/min, diastolic dysfunction > grade 1 on echocardiography, pulmonary hypertension, weight loss >10% in the last 6 months with unknown cause.
  • - Contra-indications for methylprednisolone, such as pregnancy, lactation, psychotic or depressive disorder, ulcus duodeni or ventriculi, untreated hypertension (> 160/90 mmHg) or acute infections.

研究者

相似试验